Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles

Biomaterials

Volumn 53, Issue , 2015, Pages 370-378

  Hu, Qizhi ^a,b   Rijcken, Cristianne J ^b   Bansal, Ruchi ^a   Hennink, Wim E ^c   Storm, Gert ^a,c   Prakash, Jai ^a,d  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b Cristal Therapeutics   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antitumour efficacy; Breast cancer; Docetaxel; Polymeric micelles; Tumour targeting

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG PRODUCTS; MAMMALS; MICELLES; TUMORS;

ANTITUMOUR EFFICACY; BREAST CANCER; CROSS-LINKED POLYMERIC MICELLES; DOCETAXEL; INTRAVENOUS INJECTIONS; PHYSIOLOGICAL CONDITION; POLYMERIC MICELLE; THERAPEUTIC EFFICACY;

POLYMERS;

COPOLYMER; DOCETAXEL; ESTER; POLY(ETHYLENE GLYCOL)BETA POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE LACTATE]COPOLYMER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MICELLE; TAXOID;

ACUTE TOXICITY; AGRANULOCYTOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; COVALENT BOND; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PURIFICATION; DRUG SYNTHESIS; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SURVIVAL; SUSTAINED DRUG RELEASE; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; BREAST NEOPLASMS; MICELLE; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALIA; MUS; RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICELLES; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS;

EID: 84927939885     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.085     Document Type: Article

References (52)

1. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
2. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. JClin Oncol 2013, 31:2205-2218.
3. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
4. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
5. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. JControl Release 2012, 161:175-187.
6. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
7. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
8. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2007, 2:751-760.
9. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging invivo. Adv Drug Deliv Rev 2013, 65:71-79.
10. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217.
11. Larson N., Ghandehari H. Polymeric conjugates for drug delivery. Chem Mater 2012, 24:840-853.
12. Kato K., Chin K., Yoshikawa T., Yamaguchi K., Tsuji Y., Esaki T., et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs 2012, 30:1621-1627.
13. Cabral H., Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. JControl Release 2014, 190:465-476.
14. 2. Ann Oncol 2000, 11:1029-1033.
15. Winer E.P., Berry D.A., Woolf S., Duggan D., Kornblith A., Harris L.N., et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group b trial 9342. JClin Oncol 2004, 22:2061-2068.
16. ®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
17. Zhang J., Liu J. Tumor stroma as targets for cancer therapy. Pharmacol Ther 2013, 137:200-215.
18. Mueller M.M., Fusenig N.E. Friends or foes -bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
19. Cortes J.E., Pazdur R. Docetaxel. JClin Oncol 1995, 13:2643-2655.
20. Lyseng-Williamson K.A., Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005, 65:2513-2531.
21. Michael A., Syrigos K., Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis 2009, 12:13-16.
22. Baker J., Ajani J., Scotté F., Winther D., Martin M., Aapro M.S., et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009, 13:49-59.
23. Zhang L., Zhang N. How nanotechnology can enhance docetaxel therapy. Int J Nanomedicine 2013, 8:2927-2941.
24. Huang J., Zhang H., Yu Y., Chen Y., Wang D., Zhang G., et al. Biodegradable self-assembled nanoparticles of poly (d,l-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. Biomaterials 2014, 35:550-566.
25. Ernsting M.J., Tang W.-L., MacCallum N.W., Li S.-D. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 2012, 33:1445-1454.
26. Liu Z., Liu D., Wang L., Zhang J., Zhang N. Docetaxel-loaded pluronic p123 polymeric micelles: invitro and invivo evaluation. Int J Mol Sci 2011, 12:1684-1696.
27. Wang L., Li M., Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int J Nanomedicine 2012, 7:3281-3294.
28. Li L., Tang F., Liu H., Liu T., Hao N., Chen D., et al. Invivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 2010, 4:6874-6882.
29. Rijcken C.J., Schiffelers R.M., van Nostrum C.F., Hennink W.E. Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and invivo studies. Biomaterials 2007, 28:5581-5593.
30. Talelli M., Rijcken C.J.F., van Nostrum C.F., Storm G., Hennink W.E. Micelles based on HPMA copolymers. Adv Drug Deliv Rev 2010, 62:231-239.
31. Talelli M., Oliveira S., Rijcken C.J.F., Pieters E.H.E., Etrych T., Ulbrich K., et al. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials 2013, 34:1255-1260.
32. Crielaard B.J., Rijcken C.J., Quan L., van der Wal S., Altintas I., van der Pot M., et al. Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew Chem Int Ed Engl 2012, 51:7254-7258.
33. van Nostrum C.F., Neradovic D., Soga O., Hennink W.E. Polymeric micelles with transient stability: a novel delivery concept. Polymeric drug delivery I 2006, 40-54. American Chemical Society.
34. Rijcken C.J.F., Veldhuis T.F.J., Ramzi A., Meeldijk J.D., van Nostrum C.F., Hennink W.E. Novel fast degradable thermosensitive polymeric micelles based on PEG-block-poly(N-(2-hydroxyethyl)methacrylamide-oligolactates). Biomacromolecules 2005, 6:2343-2351.
35. Neradovic D., Soga O., Van Nostrum C.F., Hennink W.E. The effect of the processing and formulation parameters on the size of nanoparticles based on block copolymers of poly(ethylene glycol) and poly(N-isopropylacrylamide) with and without hydrolytically sensitive groups. Biomaterials 2004, 25:2409-2418.
36. Malleswara Reddy A., Banda N., Govind Dagdu S., Venugopala Rao D., Kocherlakota C.S., Krishnamurthy V. Evaluation of the pharmaceutical quality of docetaxel injection using new stability indicating chromatographic methods for assay and impurities. Sci Pharm 2010, 78:215-231.
37. Vasu Dev R., Moses Babu J., Vyas K., Sai Ram P., Ramachandra P., Sekhar N.M., et al. Isolation and characterization of impurities in docetaxel. JPharm Biomed Anal 2006, 40:614-622.
38. Kumar D., Tomar R.S., Deolia S.K., Mitra M., Mukherjee R., Burman A.C. Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation. JPharm Biomed Anal 2007, 43:1228-1235.
39. Yano T., Pinski J., Groot K., Schally A.V. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 1992, 52:4545-4547.
40. Tampellini M., Filipski E., Liu X.H., Lemaigre G., Li X.M., Vrignaud P., et al. Docetaxel chronopharmacology in mice. Cancer Res 1998, 58:3896-3904.
41. Liu J., Zahedi P., Zeng F., Allen C. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. JPharm Sci 2008, 97:3274-3290.
42. Burstein H.J., Manola J., Younger J., Parker L.M., Bunnell C.A., Scheib R., et al. Docetaxel administered on a weekly basis for metastatic breast cancer. JClin Oncol 2000, 18:1212-1219.
43. Yokoyama M. Clinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumors. JExp Clin Med 2011, 3:151-158.
44. Deng C., Jiang Y., Cheng R., Meng F., Zhong Z. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today 2012, 7:467-480.
45. Gaucher G., Dufresne M.-H., Sant V.P., Kang N., Maysinger D., Leroux J.-C. Block copolymer micelles: preparation, characterization and application in drug delivery. JControl Release 2005, 109:169-188.
46. Greenwald R.B., Pendri A., Bolikal D., Gilbert C.W. Highly water soluble taxol derivatives: 2'-polyethyleneglycol esters as potential prodrugs. Bioorg Med Chem Lett 1994, 4:2465-2470.
47. Kingston D.G.I., Chordia M.D., Jagtap P.G., Liang J., Shen Y.-C., Long B.H., et al. Synthesis and biological evaluation of 1-deoxypaclitaxel analogues. JOrg Chem 1999, 64:1814-1822.
48. Rijcken C. Tuneable & degradable polymeric micelles for drug delivery: from synthesis to feasibility invivo 2007, [Thesis], Utrecht University.
49. Harada M., Iwata C., Saito H., Ishii K., Hayashi T., Yashiro M., et al. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel invivo. Int J Nanomedicine 2012, 7:2713-2727.
50. Cirri P., Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 2011, 1:482-497.
51. Murakami M., Ernsting M.J., Undzys E., Holwell N., Foltz W.D., Li S.-D. Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res 2013, 73:4862-4871.
52. Bissery M.C., Nohynek G., Sanderink G.J., Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995, 6:339-355. 63-8.